David R. Simpson

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

Philippe Moreau, Tamás Masszi, Norbert Grząśko et al. · New England Journal of Medicine · 2016 · 1.1K citations · Full text

Medicine, Hematology, Pharmacotherapy +14

Probing tumor phenotypes using stable and regulated synthetic microRNA precursors

Ross A. Dickins, Michael T. Hemann, Jack T. Zilfou et al. · Nature Genetics · 2005 · 525 citations

Life Sciences, Cancer Biology, Molecular Biology +14

Oncogenic KRAS Regulates Amino Acid Homeostasis and Asparagine Biosynthesis via ATF4 and Alters Sensitivity to L-Asparaginase

Dana M. Gwinn, Alex G. Lee, Marcela Briones-Martín-del-Campo et al. · Cancer Cell · 2018 · 228 citations · Full text

Life Sciences, Genetics, Molecular Biology +10

Antitumor activity of an engineered decoy receptor targeting CLCF1–CNTFR signaling in lung adenocarcinoma

Jun W. Kim, César Márquez, Kaja Kostyrko et al. · Nature Medicine · 2019 · 79 citations · Full text

Medicine, Oncology, Pharmacology +10

Ixazomib, an Investigational Oral Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): The Phase 3 Tourmaline-MM1 Study (NCT01564537)

Philippe Moreau, Tamás Masszi, Norbert Grząśko et al. · Blood · 2015 · 69 citations

Medicine, Oncology, Pharmacology +15